Want to join the conversation?
$BIIB and Swedish Orphan Biovitrum said they will present updated data on long-term safety and efficacy of the companies' novel extended half-life therapies, ELOCTATE for hemophilia A and ALPROLIX for hemophilia B. Hemophilia is a rare, genetic disorder in which the ability of a person's blood to clot is impaired.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.